Tissue biomarkers in renal cell carcinoma: Issues and solutions

Cancer

Volumn 115, Issue SUPPL. 10, 2009, Pages 2290-2297

  Di Napoli, Arianna ^a   Signoretti, Sabina ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarker detection; Disease prognosis; Renal cell carcinoma; Tissue biomarkers

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; INTERLEUKIN 2;

CANCER RESEARCH; CONFERENCE PAPER; HUMAN; IMAGE ANALYSIS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; STANDARDIZATION; STRATIFICATION; TISSUE PRESERVATION; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; PROGNOSIS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 65949111284     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24233     Document Type: Conference Paper

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Lam JS, Klatte T, Kim HL, et al. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 2008;65:235-262.
3. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13(2 pt 2):671s-679s.
4. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13(2 pt 2):758s-763s.
5. Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol. 2007;17:331-336.
6. Escudier B. Sorafenib [corrected] in kidney cancer. Ann Oncol. 2007;18(suppl 9):ix90-ix93.
7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
8. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
10. Shaheen PE, Bukowski RM. Emerging drugs for renal cell carcinoma. Expert Opin Emerg Drugs. 2005;10:773-795.
11. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res. 2005;11:4338-4340.
12. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002;161:1961-1971.
13. Signoretti S, Bratslavsky G, Waldman FM, et al. Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res. 2008;14:3699-3705.
14. Almeida A, Paul Thiery J, Magdelenat H, Radvanyi F. Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. Anal Biochem. 2004;328:101-108.
15. Loken SD, Demetrick DJ. A novel method for freezing and storing research tissue bank specimens. Hum Pathol. 2005;36:977-980.
16. Micke P, Ohshima M, Tahmasebpoor S, et al. Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. Lab Invest. 2006;86:202-211.
17. Drubin D, Smith JS, Liu W, Zhao W, Chase GA, Clawson GA. Comparison of cryopreservation and standard needle biopsy for gene expression profiling of human breast cancer specimens. Breast Cancer Res Treat. 2005;90:93-96.
18. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49:411-424. (Pubitemid 44401549)
19. National Cancer Institute. NCI Best Practices for Biospecimen Resources. Available at: http://biospecimens.cancer.gov/biorepositories/guidelines-full- formatted.asp. Accessed May 20, 2008.
20. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-291.
21. Serrano MF, Katz M, Yan Y, Kibel AS, Humphrey PA. Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma. Cancer. 2008;113:477-483.
22. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res. 2005;11:1129-1135.
23. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol. 2006;50:1272-1277.
24. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:7388-7393.
25. DeLellis RA, Sternberger LA, Mann RB, Banks PM, Nakane PK. Immunoperoxidase techniques in diagnostic pathology. Report of a workshop sponsored by the National Cancer Institute. Am J Clin Pathol. 1979;71:483-488.
26. Taylor CR, Cote RJ.Immunomicroscopy. A Diagnostic Tool for the Surgical Pathologist. Philadelphia, Pa: Elsevier Saunders; 2005.
27. Gown AM. Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. Am J Clin Pathol. 2004;121:172-174.
28. Shi SR, Liu C, Perez J, Taylor CR. Protein-embedding technique: a potential approach to standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections. J Histochem Cytochem. 2005;53:1167-1170.
29. Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem. 2007;55:105-109. (Pubitemid 46147687)
30. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101:17174-17179.
31. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381-3385.
32. DAKO. Immunohistochemistry Standardization. DAKO Connection Brochure. Available at: http://www.dako.com/connection-brochure.pdf. Accessed October 10, 2007.
33. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721. (Pubitemid 40685588)
34. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
35. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25:4757-4764. (Pubitemid 350086478)
36. Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32:377-382.
37. Blind C, Koepenik A, Pacyna-Gengelbach M, et al. Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol. 2008;61:79-83.
38. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996;88:1054-1059.
39. DiVito KA, Charette LA, Rimm DL, Camp RL. Longterm preservation of antigenicity on tissue microarrays. Lab Invest. 2004;84:1071-1078.
40. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
41. Walker RA. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49:406-410. (Pubitemid 44401548)
42. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med. 2006;130:1026-1030.
43. DiVito KA, Camp RL. Tissue microarrays-automated analysis and future directions [serial online]. Breast Cancer Online. 2005;8;e38. Available at: http://www.bco.org. Accessed May 20, 2008.
44. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005;97:1808-1815.